What was the primary driver of Boston Scientific's significant sales growth in the first quarter of 2005?

The primary driver of Boston Scientific's significant sales growth in the first quarter of 2005 was the strong performance and market adoption of its TAXUS stent system, particularly following its launch in the U.S. in late Q1 2004. The substantial increase in U.S. net sales was largely attributable to this product, as physicians continued to convert from bare-metal stents to drug-eluting stents.

How did the company's profitability change year-over-year?

Boston Scientific experienced a substantial improvement in profitability. Net income more than doubled, increasing by 85% from $194 million in Q1 2004 to $358 million in Q1 2005. Diluted earnings per share also rose significantly, from $0.23 to $0.42. This was supported by a healthy increase in gross profit margin due to a favorable product sales mix.

What is the company's outlook regarding the drug-eluting stent market?

Boston Scientific expects continued growth in the drug-eluting stent market, projecting it to exceed $5 billion in 2005 and reach approximately $6 billion in 2006, with drug-eluting stents representing a dominant share. The company is confident in maintaining its leadership position due to positive clinical trial results, technological advantages, and a strong pipeline, but acknowledges the competitive landscape and potential market volatility.

Are there any significant legal proceedings that could impact the company?

Yes, Boston Scientific is involved in ongoing patent litigation, notably with Johnson & Johnson and Medtronic. While a recent jury found a Johnson & Johnson patent claim infringed by the older NIR® stent (which the company no longer markets), the company is appealing and does not believe it will impact current product sales like the TAXUS stent system. The company actively litigates and defends its intellectual property rights.

BSX 10-Q Quarterly Report Q1 FY2005 — Revenue, Net Income, EPS

Summary

Boston Scientific Corporation (BSX) reported a strong first quarter for 2005, with net sales surging 49% year-over-year to $1.615 billion. This impressive growth was largely driven by the successful US launch and market adoption of its TAXUS drug-eluting stent system, which saw sales jump significantly compared to the prior year. Net income also saw a substantial increase, rising 85% to $358 million, or $0.42 per diluted share. The company generated robust operating cash flow and managed its debt levels effectively, repaying a significant portion of its borrowings during the quarter. Key to this performance was the strong adoption of drug-eluting stents in the U.S., with an estimated 86% conversion rate by the end of the quarter. While international sales also grew, they were more moderate, with Japan experiencing declining stent sales due to competitive pressures. The company highlighted its ongoing investment in research and development, including a notable acquisition of Advanced Stent Technologies (AST) to bolster its stent technology portfolio, and expressed confidence in maintaining its leadership in the drug-eluting stent market, while also acknowledging the dynamic and competitive nature of the industry and ongoing patent litigation.

Key Highlights

1Net sales increased by 49% to $1.615 billion in Q1 2005 compared to Q1 2004, driven significantly by the TAXUS stent system.
2Net income rose by 85% to $358 million ($0.42 per diluted share) in Q1 2005 from $194 million ($0.23 per diluted share) in Q1 2004.
3The company reported strong operating cash flow of $441 million for the quarter.
4Acquisition of Advanced Stent Technologies (AST) in March 2005 for approximately $120 million (plus contingent consideration) to enhance stent technology and IP portfolio.
5Gross profit margin improved to 78.7% from 73.0% in the prior year, largely due to a favorable product mix.
6Significant debt repayment of $780 million during the quarter, including the maturity of $500 million senior notes.
7The US market shows strong conversion to drug-eluting stents, reaching an estimated 86% adoption rate.

BOSTON SCIENTIFIC CORP Quarterly Report for Q1 Ended Mar 31, 2005

Summary

Key Highlights

Frequently Asked Questions